Citi has commenced coverage with a 'Buy' rating and a price target of ₹1,120, which implies an upside potential of nearly 33% from the stock's closing levels on Thursday, January 22.
The brokerage's positive view is anchored in strong earnings visibility, with hospital EBITDA projected to grow at a 23% CAGR over FY26-28.
Citi expects this growth to be driven by the ramp-up of new bed capacity and margin expansion across Fortis' existing hospital network.
It also pointed to the company's solid execution track record and a well-structured expansion strategy, adding that steadily improving return on capital employed (RoCE) could support further valuation upside.
FORTIS POLL
|
Q3FY26
|
Q3FY25
|
|
REVENUE
|
2251.95
|
1928
|
17%
|
EBITDA
|
503.45
|
374.9
|
34%
|
MARGINS
|
22.4%
|
19.4%
|
15%
|
PROFIT
|
245.6
|
254.3
|
-3%
|
Fortis Healthcare's Q3 performance shows healthy topline and operating growth, compared to the year-ago period, even as net profit dipped marginally.
Revenue for the December quarter rose 17% year-on-year to ₹2,251.95 crore from ₹1,928 crore in Q3FY25. Profit fell 3% year-on-year to ₹245.6 crore, compared with ₹254.3 crore in the corresponding quarter last year.
EBITDA climbed 34% to ₹503.45 crore from ₹374.9 crore, while EBITDA margins expanded to 22.4% in Q3FY26 from 19.4% a year earlier.
Of the 17 analysts tracking Fortis Healthcare, 13 have a 'Buy' rating, while four others have a 'Hold' rating on the counter.
Shares of Fortis Healthcare closed 0.10% higher on Thursday at ₹845. The stock is down over 6% so far in 2026.
/images/ppid_59c68470-image-176914006206385114.webp)



/images/ppid_a911dc6a-image-176913922591332556.webp)
/images/ppid_a911dc6a-image-176913926271187902.webp)
/images/ppid_a911dc6a-image-176913806444455287.webp)
/images/ppid_a911dc6a-image-176913809835988995.webp)
/images/ppid_a911dc6a-image-176913802932934373.webp)
/images/ppid_a911dc6a-image-176913802753967450.webp)
/images/ppid_a911dc6a-image-176913802583672423.webp)
/images/ppid_59c68470-image-176913756553567883.webp)